AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20440639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonintensive parent training plus care-as-usual
Number of subjects: 75
Study 20440639 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 75
Study 30336805 — intervention group
Group type: EXPERIMENTAL
Intervention: ZX008 0.8 mg/kg
Number of subjects: 26
Study 30336805 — intervention group
Group type: COMPARATOR
Intervention: STP regimen (stiripentol 3,500 mg, clobazam 20 mg, valproate 25 mg/kg, max. 1,500 mg)
Number of subjects: 26
Study 30336805 — intervention group
Group type: EXPERIMENTAL
Intervention: ZX008 0.8 mg/kg + STP regimen
Number of subjects: 26
Study 14614647 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, thiazolidinediones, and acarbose
Number of subjects: 0
Study 14614647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and thiazolidinediones with sulphonylureas or meglitinides
Number of subjects: 0
Study 14614647 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0
Study 14614647 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0
Study 14614647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide and repaglinide
Number of subjects: 0
Study 14614647 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0
Study 10702176 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU)
Number of subjects: 147
Study 10702176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 9099461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adjuvant CAF chemotherapy
Number of subjects: 1572
Study 9099461 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose adjuvant CAF chemotherapy
Number of subjects: 1572
Study 9099461 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adjuvant CAF chemotherapy
Number of subjects: 1572
Study 8402326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K (1 mg/day) for 2 weeks
Number of subjects: 285
Study 8402326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K (1 mg/day) for 3 months
Number of subjects: 285
Study 8402326 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 3 months
Number of subjects: 285
Study 8402326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K (1 mg/day) for 3 months in fast losers of urinary calcium
Number of subjects: 285
Study 3081221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily for six weeks)
Number of subjects: 604
Study 3081221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 3081221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 604
Study 31665942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronox® (24 U)
Number of subjects: 250
Study 31665942 — intervention group
Group type: COMPARATOR
Intervention: Onabotulinumtoxin A (ONA) (24 U)
Number of subjects: 250
Study 31665942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronox® and ONA
Number of subjects: 250
Study 30129434 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive living healthcare aides
Number of subjects: 23
Study 30129434 — intervention group
Group type: COMPARATOR
Intervention: LTC residents
Number of subjects: 23
Study 27183454 — intervention group
Group type: EXPERIMENTAL
Intervention: Training general practitioners (GPS) in optimizing HF medication
Number of subjects: 92
Study 27183454 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 92
Study 23896197 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching group (10 s for 9 repetitions)
Number of subjects: 34
Study 23896197 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching group (30 s for 3 repetitions)
Number of subjects: 34
Study 23896197 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 22130108 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIDGES intervention
Number of subjects: 428
Study 22130108 — intervention group
Group type: COMPARATOR
Intervention: Control (services as usual wait list)
Number of subjects: 428
Study 20658830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention ('adherence improving') for patients with <95% adherence
Number of subjects: 133
Study 20658830 — intervention group
Group type: COMPARATOR
Intervention: Control group received high-quality usual care
Number of subjects: 133
Study 18544642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 10 weeks
Number of subjects: 20
Study 18544642 — intervention group
Group type: COMPARATOR
Intervention: Palmitate, tunicamycin, and thapsigargin (in vitro)
Number of subjects: 20
Study 18544642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone pretreatment (in vitro)
Number of subjects: 20
Study 16447591 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic plexus anesthesia (PPA) with 10 cc lidocaine, 2% diluted 50%
Number of subjects: 275
Study 16447591 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (control group)
Number of subjects: 275
Study 12742468 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 83
Study 12742468 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 83
Study 10569556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily for 3 months
Number of subjects: 25
Study 10569556 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 25
Study 8791132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and NSAIDs
Number of subjects: 0
Study 8791132 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in vegetables and natural fibers, low in fat
Number of subjects: 0
Study 8791132 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical exercise and maintenance of normal body weight
Number of subjects: 0
Study 8791132 — intervention group
Group type: EXPERIMENTAL
Intervention: Food fortification or supplementation
Number of subjects: 0
Study 1989710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 136
Study 1989710 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatula
Number of subjects: 136
Study 1989710 — intervention group
Group type: EXPERIMENTAL
Intervention: Swab
Number of subjects: 136
Study 6349289 — intervention group
Group type: EXPERIMENTAL
Intervention: Health motivation treatment (self-management skills, film model, verbal commitment, discussion of costs and benefits)
Number of subjects: 35
Study 6349289 — intervention group
Group type: COMPARATOR
Intervention: Aversive smoking (normally paced aversive smoking, relaxation training, role playing high risk situations, discussion of maladaptive thought patterns)
Number of subjects: 35
Study 6349289 — intervention group
Group type: EXPERIMENTAL
Intervention: Health motivation treatment
Number of subjects: 35
Study 30308287 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily drinking
Number of subjects: 55
Study 30308287 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness
Number of subjects: 55
Study 30308287 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of sleep
Number of subjects: 55
Study 30308287 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising
Number of subjects: 55
Study 30308287 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence to cope with pain without medication
Number of subjects: 55
Study 30308287 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent with a loved one
Number of subjects: 55
Study 30308287 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping behavior
Number of subjects: 55
Study 28888927 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy (CBT) for insomnia
Number of subjects: 3755
Study 28888927 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3755
Study 27094363 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Strategic Reading (CSR) instruction
Number of subjects: 0
Study 27094363 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of CSR instruction
Number of subjects: 0
Study 25364993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Interoceptive Cues (CBT‐IC)
Number of subjects: 78
Study 25364993 — intervention group
Group type: COMPARATOR
Intervention: Individual Drug Counseling (IDC)
Number of subjects: 78
Study 23140210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (insertion of written ID recommendations in clinical records)
Number of subjects: 1173
Study 23140210 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete adherence to ID recommendations
Number of subjects: 1173
Study 23140210 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate initial treatment
Number of subjects: 1173
Study 23140210 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence to recommendations
Number of subjects: 1173
Study 23140210 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson index
Number of subjects: 1173
Study 23140210 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 1173
Study 23140210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nosocomial infection
Number of subjects: 1173
Study 23140210 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 1173
Study 19355795 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 19355795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 0
Study 19355795 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol-fluticasone propionate combination (SFC)
Number of subjects: 0
Study 19355795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17706002 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Number of subjects: 0
Study 17706002 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 0
Study 15008689 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 mg transdermal nicotine patch for 4 weeks, followed by 8-week dose titration
Number of subjects: 130
Study 15008689 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine patch for 4 weeks, followed by 8-week dose titration
Number of subjects: 130
Study 15008689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine abstinence
Number of subjects: 130
Study 11156770 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing lesions
Number of subjects: 50
Study 11156770 — intervention group
Group type: EXPERIMENTAL
Intervention: New enhancing lesions
Number of subjects: 50
Study 11156770 — intervention group
Group type: EXPERIMENTAL
Intervention: New black holes
Number of subjects: 50
Study 9090787 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321
Number of subjects: 18
Study 9090787 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 18
Study 8490328 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of nasal salmon calcitonin
Number of subjects: 24
Study 8490328 — intervention group
Group type: COMPARATOR
Intervention: Nasal placebo
Number of subjects: 24
Study 2825508 — intervention group
Group type: COMPARATOR
Intervention: CTC-VCR (Vincristine)
Number of subjects: 116
Study 2825508 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-VDS (Vindesine)
Number of subjects: 116
Study 29425304 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum P1NP (N‐terminal propeptide of type‐1 collagen)
Number of subjects: 872
Study 29425304 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CTX (C‐telopeptide of type‐1 collagen)
Number of subjects: 872
Study 29425304 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1‐CTP (pyridinoline cross‐linked carboxy‐terminal telopeptide of type‐1 collagen)
Number of subjects: 872
Study 29425304 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline P1NP (>70 ng/mL)
Number of subjects: 872
Study 29425304 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline CTX (>0.299 ng/mL)
Number of subjects: 872
Study 29425304 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline 1‐CTP (>4.2 ng/mL)
Number of subjects: 872
Study 29425304 — intervention group
Group type: COMPARATOR
Intervention: None of the markers
Number of subjects: 872
Study 27552061 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g resveratrol
Number of subjects: 10
Study 27552061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23890368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon injection of 2.5 ml of 2% lidocaine
Number of subjects: 71
Study 23890368 — intervention group
Group type: COMPARATOR
Intervention: Intra‐cameral lidocaine 1%
Number of subjects: 71
Study 22790243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 21
Study 22790243 — intervention group
Group type: COMPARATOR
Intervention: Standard endovascular techniques (control)
Number of subjects: 21
Study 20035493 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction + resistance training
Number of subjects: 137
Study 20035493 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction
Number of subjects: 137
Study 18544974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) + 2 g of galacto-oligosaccharides (GOS)
Number of subjects: 30
Study 18544974 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus GG (LGG) alone (6.5 x 10(9) CFU)
Number of subjects: 30
Study 18544974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG + GOS
Number of subjects: 30
Study 15924355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal surgery
Number of subjects: 82
Study 15924355 — intervention group
Group type: COMPARATOR
Intervention: Abdominal surgery
Number of subjects: 82
Study 14556322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone
Number of subjects: 92
Study 14556322 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone and loratidine
Number of subjects: 92
Study 14556322 — intervention group
Group type: COMPARATOR
Intervention: Loratidine alone
Number of subjects: 92
Study 12721247 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin and ara‐C (IA)
Number of subjects: 34
Study 12721247 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxacitabine and ara‐C (TA)
Number of subjects: 34
Study 12721247 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxacitabine and idarubicin (TI)
Number of subjects: 34
Study 9536920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E, 400 i.u. daily for 8 weeks
Number of subjects: 20
Study 9536920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9536920 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (10 mg/min) administration
Number of subjects: 20
Study 7705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure therapy (N-CPAP) at a pressure of 10 cm H2O
Number of subjects: 7
Study 7705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Recumbent posture without N-CPAP
Number of subjects: 7
Study 7705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture without N-CPAP
Number of subjects: 7
Study 7705152 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture with N-CPAP
Number of subjects: 7
Study 7705152 — intervention group
Group type: COMPARATOR
Intervention: Any posture change or N-CPAP
Number of subjects: 7
Study 2705667 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (0.1 mg/kg, repeated every 15 minutes up to three doses)
Number of subjects: 46
Study 2705667 — intervention group
Group type: COMPARATOR
Intervention: Meperidine with dimenhydrinate (0.4 mg/kg meperidine and 25 mg dimenhydrinate, repeated every 15 minutes up to three doses)
Number of subjects: 46
Study 336647 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback Induced Anxiety
Number of subjects: 21
Study 336647 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Induced Anxiety
Number of subjects: 21
Study 336647 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 21
Study 31257407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure goal (<120 mm Hg)
Number of subjects: 9323
Study 31257407 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure goal (<140 mm Hg)
Number of subjects: 9323
Study 29282031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard argument plus narrative message
Number of subjects: 6000
Study 29282031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard argument plus inoculation message
Number of subjects: 6000
Study 29282031 — intervention group
Group type: COMPARATOR
Intervention: Control (non-advocacy based message)
Number of subjects: 6000
Study 26790259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil treatment once a week
Number of subjects: 199
Study 26790259 — intervention group
Group type: COMPARATOR
Intervention: Self-healing (control group)
Number of subjects: 199
Study 26790259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil treatment
Number of subjects: 199
Study 23392989 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid supplementation
Number of subjects: 10
Study 21441884 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical auricular acupuncture (AA)
Number of subjects: 40
Study 21441884 — intervention group
Group type: COMPARATOR
Intervention: Electrodes only (placebo)
Number of subjects: 40
Study 19366542 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II - pumping warm saline into the abdomen until it spilled out of the open ports
Number of subjects: 40
Study 19366542 — intervention group
Group type: COMPARATOR
Intervention: Group I - evacuation of residual CO(2) by abdominal oppression
Number of subjects: 40
Study 16404275 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b
Number of subjects: 34
Study 16404275 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone (Control)
Number of subjects: 34
Study 15309242 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (group Ia)
Number of subjects: 144
Study 11386980 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (100 microgram)
Number of subjects: 50
Study 11386980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9255002 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cord clamping (n = 48)
Number of subjects: 107
Study 9255002 — intervention group
Group type: COMPARATOR
Intervention: Late cord clamping (n = 59)
Number of subjects: 107
Study 8290211 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified trabeculotomy ab externo (TAB), n = 44
Number of subjects: 79
Study 8290211 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with adjunctive mitomycin C (TMC), n = 35
Number of subjects: 79
Study 3297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin loss, intestinal plasma loss (measured by intestinal alpha 1-antitrypsin clearance), occurrence of inflammatory cells (leukocytes) in feces.
Number of subjects: 31
Study 3297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Leakage of antileukoprotease from the respiratory tract into the blood.
Number of subjects: 31
Study 3297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of current grading system and SAL (serum albumin loss).
Number of subjects: 31
Study 31035497 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Dietary Diversity Score (DDS) quartile
Number of subjects: 6587
Study 31035497 — intervention group
Group type: COMPARATOR
Intervention: Lowest Dietary Diversity Score (DDS) quartile
Number of subjects: 6587
Study 28585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-based exercise program (n = 14), 2-month duration, 3 sessions per week, including training games for aerobic endurance, balance, and isometric strength
Number of subjects: 27
Study 28585394 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 27
Study 28585394 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-based exercise program (n = 14)
Number of subjects: 27
Study 26338348 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 95
Study 26338348 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 95
Study 23445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench Press (BP) exercise
Number of subjects: 42
Study 23445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg Press (LP) exercise
Number of subjects: 42
Study 23445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BP and LP exercises
Number of subjects: 42
Study 23445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CK peaks after LP and BP
Number of subjects: 42
Study 23445920 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement of classification between exercises
Number of subjects: 42
Study 22027646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of micronutrients (Orthomol vital m/f) for three months
Number of subjects: 40
Study 22027646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no micronutrient supplementation)
Number of subjects: 40
Study 22027646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of micronutrients (Orthomol vital m/f)
Number of subjects: 40
Study 22027646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of micronutrients (Orthomol vital m/f) in male subjects
Number of subjects: 40
Study 18648875 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMIS laparoscopic simulator
Number of subjects: 160
Study 18218204 — intervention group
Group type: EXPERIMENTAL
Intervention: HNPPV group (n=20) with conventional therapy and HNPPV
Number of subjects: 40
Study 18218204 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20) with conventional therapy only
Number of subjects: 40
Study 14767751 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (180,000 IU a day before HDMTX)
Number of subjects: 35
Study 14767751 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate (HDMTX) only
Number of subjects: 35
Study 11834237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cellulose sulfate (CS), 7 consecutive daily doses
Number of subjects: 36